Budd G T, Webster K D, Reimer R R, Martimbeau P, Livingston R B
J Surg Oncol. 1983 Nov;24(3):192-5. doi: 10.1002/jso.2930240309.
A retrospective analysis of 42 patients with stage III, IV, or recurrent epithelial ovarian carcinoma treated with monthly cisplatin, Adriamycin, and cyclophosphamide (PAC) was made. Of 36 patients with measurable disease, 18 (50%) achieved a clinical complete response (CR) and 12 (33%) achieved a partial response (PR) for an objective response rate of 83%. Six stage III patients remained without measurable disease after surgery and postoperative PAC and are included in the survival data. The median survival of all patients was 22 months (10 months for nonresponders), with a median duration of response of 15 months (19+ months for clinical complete responders). Of 16 patients who underwent second-look laparotomy while in clinical CR, 8 were pathologically free of disease. Of these 8 surgically staged CRs, 2 have suffered CNS relapses, while the rest remain free of disease. One additional patient, who had been found to have only microscopic disease at the time of second-look surgery, subsequently relapsed in the CNS, for a total of 3 patients with CNS relapse. We conclude that PAC is an effective regimen, but that prolonged survival of these patients may put them at greater risk for CNS relapse.
对42例接受每月顺铂、阿霉素和环磷酰胺（PAC）治疗的III期、IV期或复发性上皮性卵巢癌患者进行了回顾性分析。在36例可测量疾病的患者中，18例（50%）达到临床完全缓解（CR），12例（33%）达到部分缓解（PR），客观缓解率为83%。6例III期患者在手术及术后PAC治疗后仍无可测量疾病，其纳入生存数据。所有患者的中位生存期为22个月（无反应者为10个月），中位缓解持续时间为15个月（临床完全缓解者为19 +个月）。在16例处于临床CR时接受二次剖腹探查的患者中，8例病理检查无疾病。在这8例手术分期为CR的患者中，2例发生中枢神经系统复发，其余患者仍无疾病。另外1例患者在二次探查手术时仅发现微小疾病，随后中枢神经系统复发，共有3例患者发生中枢神经系统复发。我们得出结论，PAC是一种有效的治疗方案，但这些患者的长期生存可能使他们面临更高的中枢神经系统复发风险。
